Verona Pharma partners with Ritedose to deliver Ohtuvayre drug for COPD

Verona Pharma is partnering with Ritedose, the largest sterile contract development manufacturing organization – CDMO – in the U.S. specializing in sterile Blow Fill Seal production of unit dose solutions for the ophthalmic and respiratory markets, as the development and manufacturing partner of Ohtuvayre, a new novel product for Chronic Obstructive Pulmonary Disease or COPD. The FDA approved Ohtuvayre on June 26 for the maintenance treatment of COPD in adult patients. It is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years. Despite maintenance therapy in multiple combinations, most COPD patients grapple with daily symptoms including breathlessness and persistent coughing. COPD affects more than 480 million people across the globe and more than 14 million people in the United States.